Evidence map›Paper›PMID 33561464›Full record

ReviewDrug discovery today2021

Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma.

Hong Zhang, Kristen Spencer, Stephen K Burley, X F Steven Zheng

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug discovery today, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
3.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Tamoxifen for adults with hepatocellular carcinoma.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Constitutively Active Androgen Receptor in Hepatocellular Carcinoma.International journal of molecular sciences · 2022
    Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Hong ZhangRutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA; Department of Pharmacology, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, 675 Hoes Lane, Piscataway, NJ 08854, USA.
Kristen SpencerRutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA; Department of Medicine, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, 125 Paterson Street, New Brunswick, NJ 08901, USA.
Stephen K BurleyRutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA; RCSB Protein Data Bank and Institute for Quantitative Biomedicine, Rutgers, The State University of New Jersey, 174 Frelinghuysen Road, Piscataway, NJ 08854, USA; Department of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey, 174 Frelinghuysen Road, Piscataway, NJ 08854, USA; RCSB Protein Data Bank, School of Pharmacy and Pharmaceutical Sciences and San Diego Supercomputing Center, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
X F Steven ZhengRutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA; Department of Pharmacology, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, 675 Hoes Lane, Piscataway, NJ 08854, USA. Electronic address: zhengst@cinj.rutgers.edu.
Rutgers, The State University of New Jersey · USSan Diego Supercomputer Center · US

Funding

TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Chang S Chan · 1997 to 2026
$94.5M
PDB MANAGEMENT BY THE RESEARCH COLLABORATORY FOR STRUCTURAL BIOINFORMATICSR01GM133198 · NIGMS · RUTGERS, THE STATE UNIV OF N.J. · PI BURLEY, STEPHEN K · 2019 to 2023
$19.3M
Growth Control and Anti-Cancer MechanismsR01CA123391 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI ZHENG, STEVEN · 2007 to 2016
$2.9M
Oncogenic Chromatin Remodeling and Anticancer MechanismsR01CA280177 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI STEVEN ZHENG · 2023 to 2026
$1.8M
Metabolic Control and Anticancer MechanismR01CA260006 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI STEVEN ZHENG · 2021 to 2026
$1.7M
Amino Acids-Rab1A Nutrient Signaling in the Regulation of Glucose HomeostasisR01DK124897 · NIDDK · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI ZHENG, STEVEN · 2020 to 2023
$1.5M
NCI NIH HHS P30 CA072720NCI NIH HHS R01 CA123391NCI NIH HHS R01 CA260006NCI NIH HHS R01 CA280177NIDDK NIH HHS R01 DK124897NIGMS NIH HHS R01 GM133198
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the predominant form of liver cancer and a leading cause of cancer deaths worldwide. HCC is a male-dominant cancer with a male:female ratio of up to 7:1. The androgen receptor (AR) is the male hormone receptor known as a major oncogenic driver of prostate cancer. Although AR has been linked to the sexual dimorphism of HCC, clinical trials with AR-targeted agents failed to generate survival benefits. Recent studies provide new insights into the role of AR in liver tumorigenesis and therapeutic responses. Herein, we review current understanding of AR signaling in HCC and feedback mechanisms that limit response to AR blockade. New AR-targeting strategies that might improve outcomes in HCC therapies are also discussed.

Indexed as

AnimalsAntineoplastic AgentsCarcinoma, HepatocellularFemaleHumansLiver NeoplasmsMaleMolecular Targeted TherapyReceptors, AndrogenSex CharacteristicsSex DistributionSignal TransductionSurvivalAntineoplastic AgentsAR protein, humanReceptors, Androgen

Identifiers

PMID33561464
PMCPMC8222101
OpenAlexW3126736449

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.